Anthem · Tirzepatide · US health-plan appeal rights

Tirzepatide denied for failing step therapy by Anthem?

Q: How long do I have to appeal a Anthem Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Tirzepatide

## Anthem Step-Therapy Denials for Tirzepatide (Mounjaro/Zepbound): The NQTL Parity Attack

Anthem BCBS's step-therapy denial of tirzepatide is the most defeatable denial category in the GLP-1 space — provided you frame it correctly. Anthem routes tirzepatide through CarelonRx (its in-house PBM, formerly IngenioRx), and the standard fail-first ladder under Anthem Clinical Criteria CC-0019 (Antidiabetic Agents) and the parallel CC-0001 weight-management framework requires documented inadequate response to metformin plus a sulfonylurea, DPP-4, or SGLT2 inhibitor before semaglutide, with tirzepatide gated behind semaglutide failure. This sequencing is contractually defensible only if Anthem's own continuity-of-care and override pathways are honored — and they routinely are not.

The federal lever is 29 USC §1185d (ACA §2706, codified through the Consolidated Appropriations Act step-therapy provisions adopted by most Anthem fully-insured plans) combined with state step-therapy override statutes — Indiana IC §27-1-37.6, Kentucky KRS §304.17A-163, California Health & Safety Code §1367.241, New York Ins. Law §4903(c-1), and Georgia OCGA §33-24-59.25 all require Anthem to grant an override within 72 hours (24 if urgent) when (i) the required drug is contraindicated, (ii) the patient previously tried and failed the step-therapy drug on any plan, (iii) the patient is stable on tirzepatide, or (iv) the step drug is expected to be ineffective based on clinical characteristics. Anthem's internal Step Therapy Exception Request Form (CarelonRx fax 1-844-490-4877) is the correct channel — not the generic prior auth form, which CarelonRx will recycle through the same denial logic.

For T2DM patients with HbA1c ≥6.5% within 12 months, the strongest argument cites ADA 2024 Standards of Care §9 (pharmacologic therapy), which positions tirzepatide as a preferred agent for patients with established ASCVD, HFrEF, or BMI ≥27 — bypassing the metformin-first hierarchy. Attach the CGM data, A1c trend, and any documented metformin GI intolerance or eGFR <30 contraindication.

If Anthem's internal appeal fails, escalate to external review under 29 CFR §2560.503-1(h) for ERISA plans or your state DOI for fully-insured. The NQTL parity argument under 29 CFR §2590.712 is underused here: Anthem applies stricter step-therapy edits to GLP-1s for obesity than for diabetes despite identical molecular entities, a quantifiable parity violation post-2024 MHPAEA final rule.

Tactical tip: Request Anthem's NQTL comparative analysis under 29 CFR §2590.712(d)(3) in your appeal. Anthem is obligated to produce it within 30 days, and the documentation almost always reveals inconsistent application of the step requirement — which functions as a settlement lever before the external review even concludes.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Tirzepatide

Other denial reasons for Anthem Tirzepatide

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.